Biogen withdraws MAA for aducanumab for the treatment of the early stages of Alzheimer’s disease

Apr 22, 2022

Biogen announced that it has withdrawn the MAA for aducanumab for the treatment of the early stages of Alzheimer’s disease, following feedback from the CHMP suggesting the data provided would not be sufficient to support a positive opinion.

Print Page Mail Article